ASCO 2026 | The future of antibody-drug conjugates in endometrial cancer

Linda Mileshkin • 30 May 2026

ASCO 2026

BLUESTAR

Linda Mileshkin, MBBS, MD, Peter MacCallum Cancer Center, Melbourne, Australia, discusses the efficacy of the antibody-drug conjugate (ADC) puxitatug samrotecan (puxi-sam) in relapsed/metastatic endometrial cancer from the BLUESTAR trial (NCT01523482), highlighting the strong 60% response rate in patients previously treated with platinum-based chemotherapy and immunotherapy. Puxi-sam has received breakthrough therapy designation from the FDA and is now being evaluated in a Phase III trial. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.